$AXE Strengthens biochip manufacturing
Key biosensor components of Archer’s lab-on-a-chip device miniaturised to nanosize chip formats, a requirement for successful biochip development.
• Archer team grows, introducing world-class expertise and capabilities spanning
nanotechnology, advanced materials, and molecular biology.
• The Company is utilising over $150 million of sophisticated chip building facilities
in Australia to manufacture its graphene-based biochip technology.
• Lab-on-a-chip devices form part of the multibillion dollar deep-tech economy,
catalysed by the global need for point of care medical diagnostics and testing†,‡.
• Archer team grows, introducing world-class expertise and capabilities spanning
nanotechnology, advanced materials, and molecular biology.
• The Company is utilising over $150 million of sophisticated chip building facilities
in Australia to manufacture its graphene-based biochip technology.
• Lab-on-a-chip devices form part of the multibillion dollar deep-tech economy,
catalysed by the global need for point of care medical diagnostics and testing†,‡.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。